7.43
price up icon17.75%   1.12
after-market 시간 외 거래: 7.17 -0.26 -3.50%
loading
전일 마감가:
$6.31
열려 있는:
$6.22
하루 거래량:
163.16K
Relative Volume:
1.39
시가총액:
$138.59M
수익:
-
순이익/손실:
$-22.38M
주가수익비율:
-4.7935
EPS:
-1.55
순현금흐름:
$-15.54M
1주 성능:
-5.59%
1개월 성능:
+21.80%
6개월 성능:
-8.72%
1년 성능:
-22.28%
1일 변동 폭
Value
$6.00
$7.48
1주일 범위
Value
$6.00
$8.2399
52주 변동 폭
Value
$5.85
$12.10

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name
명칭
Nuvectis Pharma Inc
Name
전화
360-837-7232
Name
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Name
직원
13
Name
트위터
Name
다음 수익 날짜
2024-08-07
Name
최신 SEC 제출 서류
Name
NVCT's Discussions on Twitter

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-07-13 개시 Ladenburg Thalmann Buy

Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스

pulisher
07:02 AM

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

07:02 AM
pulisher
Nov 03, 2024

Trend Tracker for (NVCT) - Stock Traders Daily

Nov 03, 2024
pulisher
Oct 28, 2024

Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz

Oct 28, 2024
pulisher
Oct 28, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan

Oct 28, 2024
pulisher
Oct 23, 2024

NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Oct 23, 2024
pulisher
Oct 20, 2024

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 20, 2024
pulisher
Oct 07, 2024

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times

Oct 07, 2024
pulisher
Oct 02, 2024

Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily

Oct 02, 2024
pulisher
Sep 24, 2024

Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance

Sep 24, 2024
pulisher
Sep 21, 2024

(NVCT) Trading Advice - Stock Traders Daily

Sep 21, 2024
pulisher
Sep 19, 2024

Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR

Sep 19, 2024
pulisher
Sep 18, 2024

A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

What's Going On With Nuvve Stock? - Benzinga

Sep 18, 2024
pulisher
Sep 18, 2024

Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

ESMO where that came from: Nuvalent bags $500M on hot early data - BioWorld Online

Sep 17, 2024
pulisher
Sep 17, 2024

SEC Form 424B5 filed by Nuvalent Inc. - Quantisnow

Sep 17, 2024
pulisher
Sep 17, 2024

Why Nuvalent (NUVL) Shares Are Down 6% Today - Benzinga

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation (NASDAQ:NUVL) - Seeking Alpha

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent Inc Inc. (NUVL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Sep 17, 2024
pulisher
Sep 17, 2024

Biopharma co Nuvalent slips after upsized $500 mln stock offering priced - XM

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent 5M share Secondary priced at $100.00 - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent announces pricing of $500M upsized stock offering - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent Earns Relative Strength Rating Upgrade - Investor's Business Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvoco Vistas Corporation Block Deal | 1.2% equity worth ₹158 crore changes hands - CNBCTV18

Sep 17, 2024
pulisher
Sep 17, 2024

Nuvalent (NASDAQ:NUVL) Reaches New 1-Year High Following Analyst Upgrade - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Nuvoco Vistas sees large block trade: 45 lakh shares worth ₹158 crore - Business Upturn

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent stock outlook positive amid key questions on trial enrollment and FDA approval strategy - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvectis Pharma’s NXP900 Shows Promise in NSCLC Treatment, New Report Suggests - Vancity Buzz

Sep 16, 2024
pulisher
Sep 16, 2024

Monitoring Nuvalent Inc (NUVL) after recent insider movements - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

An analyst sees good growth prospects for Nuvation Bio Inc (NUVB) - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

Company’s Banking Shares: Up -97.40% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent gains after brokerages raise PT on promising cancer therapy data - XM

Sep 16, 2024
pulisher
Sep 16, 2024

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch - BioSpace

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent Shares Gain on Cancer Drug Trial Updates - MarketWatch

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent price target raised to $132 from $102 at BMO Capital - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent announces $350M offering of Class A common stock - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Nuvalent Announces Public Offering of Common Stock - Yahoo Finance

Sep 16, 2024
pulisher
Sep 13, 2024

NUVVE ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT - Nasdaq

Sep 13, 2024
pulisher
Sep 12, 2024

Nuvalent (NASDAQ:NUVL) Stock Price Down 3.9% on Insider Selling - MarketBeat

Sep 12, 2024
pulisher
Sep 11, 2024

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 8.5% - MarketBeat

Sep 11, 2024
pulisher
Sep 11, 2024

Nuvectis Pharma (NASDAQ:NVCT) Trading Down 8.5% - Defense World

Sep 11, 2024
pulisher
Sep 09, 2024

Nuvectis’ NXP800 gains FDA ODD for cancer treatment - MSN

Sep 09, 2024
pulisher
Sep 07, 2024

Insider Buyers Lose Additional US$46k As Nuvectis Pharma Dips To US$115m - Simply Wall St

Sep 07, 2024
pulisher
Sep 05, 2024

When (NVCT) Moves Investors should Listen - Stock Traders Daily

Sep 05, 2024
pulisher
Sep 05, 2024

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 05, 2024
pulisher
Sep 02, 2024

Nuvectis Pharma Inc (NVCT) Becoming More Attractive for Investors - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Is Nuvectis Pharma Inc (NVCT) worth investing in despite its overvalued state? - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

The time has not yet come to remove your chips from the table: Nuvectis Pharma Inc (NVCT) - SETE News

Sep 02, 2024

Nuvectis Pharma Inc (NVCT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Nuvectis Pharma Inc 주식 (NVCT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
BENTSUR RON
Chairman & CEO
May 10 '24
Buy
6.40
2,000
12,800
3,244,484
Poradosu Enrique
Chief Science & Business Off
May 10 '24
Buy
6.29
500
3,145
1,504,319
Shemesh Shay
Chief Dev. & Ops. Officer
May 10 '24
Buy
6.32
1,113
7,034
1,493,068
BENTSUR RON
Chairman & CEO
Mar 18 '24
Buy
10.29
5,000
51,450
3,242,484
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):